Pulmonx Corp
LUNG
Get informed when a big investor buys or sells
+ FollowMarket Cap$78.14M
Close$
$6.39
245.3% upside
Current Fair Value
245.3% upsideUndervalued by 245.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $78.14 Million |
|---|---|
| Enterprise Value | $78.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.33 |
| Beta | 0.28 |
| Outstanding Shares | 42,184,793 |
Return
| Return on Equity | -122.76% |
|---|---|
| Return on Assets | -41.94% |
| Return on Invested Capital | -47.27% |
Valuation & Multiples
| P/E Ratio | -1.61 |
|---|---|
| PEG | 4.79 |
| Price to Sales | 0.93 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.9 |
| Enterprise Value to EBIT | -1.77 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.72 |
| Debt to Equity | 1.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$22.39 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.26
Average shareholder expectationRevenue Estimate
$21.93 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 7.1233▲ 712.33% |
|---|---|
| Total Calls | 57,600▲ Infinity% |
| Total Puts | 410,300▲ 281.32% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 62.13%▼ 13.76% |
|---|---|
| Total Invested | $34.07M▼ 16.93% |
| Investors Holding | 112▼ 4.00% |
ESG Score
No data
About Pulmonx Corp
220 employeesPulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System...